CN108272751A - A kind of vitamin K drops and preparation method thereof - Google Patents
A kind of vitamin K drops and preparation method thereof Download PDFInfo
- Publication number
- CN108272751A CN108272751A CN201810243587.7A CN201810243587A CN108272751A CN 108272751 A CN108272751 A CN 108272751A CN 201810243587 A CN201810243587 A CN 201810243587A CN 108272751 A CN108272751 A CN 108272751A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- drops
- alginate
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of vitamin K drops, are prepared by the following raw material：Vitamin K1, farnoquinone, vitamin E, casein phosphopeptide, medium chain triglyceride, conjugated linoleic acid, alginate, tragacanth, antioxidant, emulsifier.The present invention also provides the preparation methods of this vitamin K drops.Vitamin K drops provided by the invention is suitable for infant replenishing vitamins K, and dosage is accurate, easy to use.
Description
Technical field
The present invention relates to drug fields, and in particular to a kind of vitamin K drops and preparation method thereof.
Background technology
Vitamin K is one of indispensable important vitamin in human body.However due to vitamin K and intestines in many foods
Road bacterium can generate vitamin K, and health adult remembers that older children will not generally supply lacking for insufficient generation vitamin K because of diet
It is weary.But ewborn infant is easy to happen out because because physical efficiency enteric bacteria is less, causing endogenous microbes vitamin K insufficient in vivo
Blood.The breakthrough of Serum Vitamin K and protein induced by vitamin K absence Ⅱ detection technique in recent years reports numerous in succession both at home and abroad
The article to cause bleeding by the shortage of vitamin K in relation to baby, it is believed that the shortage of vitamin K be worldwide baby's hemorrhagic disease and
Dead major reason.Vitamin K preparation can effectively restore factor to normal level and control bleeding.
The preparation of current replenishing vitamins K single on the market is less, and generally tablet, adult type soft capsule and injection
Agent.And the dosage of tablet and soft capsule is not suitable for being applied to infant, only injection agent dose is accurate, but injection application is not square
Just, safety is not as good as oral preparation.
Invention content
In view of the above-mentioned defects in the prior art, the object of the present invention is to provide one kind being suitable for infant replenishing vitamins K,
And dosage is accurate, vitamin K drops easy to use；
It is a further object of the present invention to provide a kind of preparation methods of vitamin K drops.
The purpose of the present invention is what is realized by following technical solution：
Vitamin K drops of the present invention, it is prepared by the raw material of following parts by weight：
0.010-0.013 parts of vitamin K1, farnoquinone 5-6.5,0.2-0.5 parts of vitamin E, casein phosphopeptide 1-3
Part, 64-80 parts of medium chain triglyceride, 25-38 parts of conjugated linoleic acid, 1-3 parts of alginate, tragacanth 3-7, emulsifier 0.5-
2 parts.
Preferably：
0.011-0.012 parts of vitamin K1, farnoquinone 5.5-6,0.3-0.4 parts of vitamin E, casein phosphopeptide 1-2
Part, 70-75 parts of medium chain triglyceride, 30-35 parts of conjugated linoleic acid, 1-2 parts of alginate, 4-6 parts of tragacanth, emulsifier 1-
1.5 part.
Preferably, the alginate is sodium alginate and/or potassium alginate.
The emulsifier is polyglyceryl fatty acid ester, Tween-80, citric acid fatty acid glycerine
One or more kinds of mixtures in ester.
The vitamin K drops, preparation method includes the following steps：
(1) vitamin K1, farnoquinone are added in medium chain triglyceride, are added under conditions of temperature is 38-42 DEG C
Tragacanth stirs evenly, and is cooled to room temperature, obtains mixed liquor A；
(2) conjugated linoleic acid and alginate are added in mixed liquor A at room temperature, are stirred evenly；
(3) vitamin E, casein phosphopeptide and emulsifier are continuously added, is stirred evenly, mixed oil liquid is obtained.
The vitamin K drops, preparation method are further comprising the steps of：
It will be prepared into capsule-type drops in the mixed oil liquid injection capsule skin of gained.
It, will more with caution, in the present invention for the selection of auxiliary material as infant's oral medication：
Medium chain triglyceride：As solvent, compared with common grease and hydrogenated oil and fat, medium chain triglyceride unsaturated lipid
The content of fat acid is extremely low, and oxidation stability is very good, is entirely odorless, colourless transparency liquid；Since its carbochain is short, so,
Its emulsion stability, dissolubility, extensibility and lubricity is better than common grease, is functionality nontoxic, that safety is high
Grease.
Conjugated linoleic acid：Can not only be used for solvent and nutrient needed by human, can enhance human body oxidation resistance and
Immunocompetence, enhancing development.
Vitamin E：Not only it is used as antioxidant, but also human body replenishing vitamins E can be given.
Casein phosphopeptide：As nutrition fortifier, the absorption and utilization of calcium can be promoted, improve the metals such as iron, zinc, magnesium from
The bioavilability of son.
Alginate：The emulsifier and thickener of food-grade, it is nontoxic.
Tragacanth：Odorless, tasteless, mouthfeel stick-slip coordinate with alginate, assign the glutinous profit of solution, suitable for baby mouth
Sense, and have emulsification, the effect of stablizing solution state concurrently.
Antioxidant selected by the present invention and emulsifier are auxiliary material specified in health products systems for recording, as infant
The auxiliary material of medication is safe and stable.
A kind of vitamin K drops provided by the invention and preparation method thereof has the following advantages：
1, vitamin K drops provided by the invention is designed for infant, and dosage and dosage form have fully considered infant
Suitability, accuracy and the convenience of medication can safely and effectively supplement the K element of infant's shortage；
2, the invention coordinates medium chain triglyceride and conjugated linoleic acid jointly, as vitamin K drops
Solvent, not only palatability is good, and each side's surface properties of drops are superior, and can also supplement substance necessary to infant's body simultaneously,
Enhance the oxidation resistance and immunocompetence of human body, enhancing development；
3, the addition sequence of supplementary material has a significant impact to the stability of preparation, the preparation method of vitamin K of the present invention, first
Vitamin K, medium chain triglyceride and tragacanth are stirred evenly in suitable temperature range, increase vitamin K in solvent
In solubility, reach a dissolution equilibrium, add conjugated linoleic acid and alginate, just do not interfere with vitamin K so
In the stability and dissolubility of two kinds of in the mixed solvents, it is eventually adding emulsifier and vitamin E, casein phosphopeptide, further
Improve the stability of oil-based solvent and the stability of vitamin K.
Specific implementation mode
It is further illustrated the present invention below by embodiment.It should be understood that the embodiment of the present invention is for illustrating
The present invention is rather than limiting the invention.The simple modifications that essence according to the present invention carries out the present invention belong to the present invention
Claimed range.
Embodiment 1
Vitamin K drops of the present invention, it is prepared by the following raw material and auxiliary material：
Vitamin K1 0.010g, farnoquinone 5g, vitamin E 0.2g, casein phosphopeptide 1g, medium chain triglyceride
64g, conjugated linoleic acid 38g, sodium alginate 1g, tragacanth 3g, polyglyceryl fatty acid ester 0.5g.
The vitamin K drops, preparation method includes the following steps：
(1) vitamin K1, farnoquinone are added in medium chain triglyceride, it is yellow that west is added under conditions of temperature is 38 DEG C
Stilbene glue stirs evenly, and is cooled to room temperature, obtains mixed liquor A；
(2) conjugated linoleic acid and sodium alginate are added in mixed liquor A at room temperature, are stirred evenly；
(3) vitamin E, casein phosphopeptide and polyglyceryl fatty acid ester are continuously added, is stirred evenly, mixed oil liquid is obtained.
Embodiment 2
Vitamin K drops of the present invention, it is prepared by the following raw material and auxiliary material：
Vitamin K1 0.013g, farnoquinone 6.5g, vitamin E 0.5g, casein phosphopeptide 3g, medium chain triglyceride
80g, conjugated linoleic acid 25g, potassium alginate 3g, tragacanth 7g, emulsifier 2g.
The emulsifier is the mixture of Tween-80, citric acid fatty glyceride.
The vitamin K drops, preparation method includes the following steps：
(1) vitamin K1, farnoquinone are added in medium chain triglyceride, it is yellow that west is added under conditions of temperature is 42 DEG C
Stilbene glue stirs evenly, and is cooled to room temperature, obtains mixed liquor A；
(2) conjugated linoleic acid and potassium alginate are added in mixed liquor A at room temperature, are stirred evenly；
(3) vitamin E, casein phosphopeptide and Tween-80, citric acid fat are continuously added
The mixture of acid glyceride, stirs evenly, and obtains mixed oil liquid.
Embodiment 3
Vitamin K drops of the present invention, it is prepared by the following raw material and auxiliary material：
Vitamin K1 0.011g, farnoquinone 5.5g, vitamin E 0.3g, casein phosphopeptide 1.2g, medium chain triglyceride three
Ester 75g, conjugated linoleic acid 30g, sodium alginate 1.2g, tragacanth 4g, citric acid fatty glyceride 1g.
The vitamin K drops, preparation method includes the following steps：
(1) vitamin K1, farnoquinone are added in medium chain triglyceride, it is yellow that west is added under conditions of temperature is 39 DEG C
Stilbene glue stirs evenly, and is cooled to room temperature, obtains mixed liquor A；
(2) conjugated linoleic acid and sodium alginate are added in mixed liquor A at room temperature, are stirred evenly；
(3) vitamin E, casein phosphopeptide and citric acid fatty glyceride are continuously added, stirs evenly, obtains miscella
Liquid；
(4) mixed oil liquid of gained is injected in capsule skin and is prepared into capsule-type drops.
Embodiment 4
Vitamin K drops of the present invention, it is prepared by the following raw material and auxiliary material：
Vitamin K1 0.011g, farnoquinone 6g, vitamin E 0.4g, casein phosphopeptide 1.5g, medium chain triglyceride
70g, conjugated linoleic acid 35g, potassium alginate 1.5g, tragacanth 6g, emulsifier 1.5g.
The emulsifier is the mixture of polyglyceryl fatty acid ester, Tween-80.
The vitamin K drops, preparation method includes the following steps：
(1) vitamin K1, farnoquinone are added in medium chain triglyceride, it is yellow that west is added under conditions of temperature is 41 DEG C
Stilbene glue stirs evenly, and is cooled to room temperature, obtains mixed liquor A；
(2) conjugated linoleic acid and potassium alginate are added in mixed liquor A at room temperature, are stirred evenly；
(3) vitamin E, casein phosphopeptide and emulsifier are continuously added, is stirred evenly, mixed oil liquid is obtained；
(4) mixed oil liquid of gained is injected in capsule skin and is prepared into capsule-type drops.
Embodiment 5
Vitamin K drops of the present invention, it is prepared by the following raw material and auxiliary material：
Vitamin K1 0.0125g, farnoquinone 6g, vitamin E 0.35g, casein phosphopeptide 2g, medium chain triglyceride
73g, conjugated linoleic acid 32g, sodium alginate 2g, tragacanth 4g, polyglyceryl fatty acid ester 1.5g.
The vitamin K drops, preparation method includes the following steps：
(1) vitamin K1, farnoquinone are added in medium chain triglyceride, it is yellow that west is added under conditions of temperature is 40 DEG C
Stilbene glue stirs evenly, and is cooled to room temperature, obtains mixed liquor A；
(2) conjugated linoleic acid and sodium alginate are added in mixed liquor A at room temperature, are stirred evenly；
(3) vitamin E, casein phosphopeptide and polyglyceryl fatty acid ester are continuously added, is stirred evenly, mixed oil liquid is obtained.
Embodiment 6
Clinical test
1, research object：Ewborn infant 120, gestational age 38-41 weeks, weight 2500g-4000g, Pure breast feeding, apgar
Scoring >=8, no congenital malformations and other important diseases.
2, experiment grouping：120 babies are divided into experimental group I (selective vitamin K injection intervention group), reality by randomized
Test three groups, each 40 of II (selective vitamin K drops intervention group) of group and control group (conventional vitamin K intervention groups).Acquire baby
Youngster's bleeding of the umbilicus 1ml is set in disinfection anticoagulant tube, carries out the detection of II concentration of blood plasma PIVKA-.
Three groups of whole 120 subjects measure II positives of bleeding of the umbilicus PIVKA- 48, positive rate 40% altogether.48 positives
The equal 64 μ g/ml of ＜ of II concentration of PIVKA- of person；Experimental group I, experimental group II and II positives of control group bleeding of the umbilicus PIVKA- are respectively
15,17,16, positive rate is respectively 37.5%, 42.5%, 40%.The positive situations of three groups of bleeding of the umbilicus PIVKA- II are through statistics
Credit is analysed, no significant difference.
3, dosage regimen
Experimental group I:According to II testing results of bleeding of the umbilicus PIVKA-, it is resolved that each baby's vitamin K selective application is specific
Method.Specific method:1. the intervention of II positives of PIVKA-:The 1st day intramuscular injection vitamin K injection 1mg that be born is primary, the 10th day
Rise and be changed to take orally, vitamin K tablet half is dissolved in water and feeds, about 2.5mg, every 10 days of Isodose it is oral it is primary × 9 times, totally 10
It is secondary；2. II negative patients of PIVKA-:21 negative patients not supplement；3. when baby (no matter its II concentration of PIVKA- normally whether) goes out
Existing special circumstances such as diarrhea, infection, disease in the liver and gallbladder etc., then additional replenishing vitamins K is primary；4. when there is allergic reaction, stand
It carves and is discontinued.
Experimental group II:According to II testing results of bleeding of the umbilicus PIVKA-, it is resolved that each baby's vitamin K selective application is specific
Method.Specific method:1. the intervention of II positives of PIVKA-:It being born the 1st day 5 drops of the oral embodiment of the present invention, 2ml is primary,
Isodose takes orally once × 9 times, 10 times totally for every 10 days from 10th day；2. II negative patients of PIVKA-:22 negative patients are not mended
It fills；3. when special circumstances such as diarrhea, infection, disease in the liver and gallbladder etc. occurs in baby (no matter its II concentration of PIVKA- normally whether), then
Additional replenishing vitamins K is primary；4. when there is allergic reaction, it is discontinued at once.
Control group:All 40 baby dues, first day conventional disposable intramuscular injection vitamin K 1mg, are not mended again later
It fills.
4, it manages
The same day after selecting tested baby's last to take medicine draws blood review time on the 90th day after that is, raw for last, and with its 1/2
Age in days 45d is done to be checked for the first time.Three groups of II concentration of baby's venous blood blood plasma PIVKA- are detected, are observed in two different days three groups
II concentration of baby's blood plasma PIVKA- and its variation.The follow-up of all babies has special messenger to be responsible for, and whether there is or not bleeding, vitamin Ks to lack for observation
The abnormal conditions such as weary, infection simultaneously supervise dispensing situation.Without mixed feeding or artificial feeding situation in the babies 3 months of whole 120
Occur.
5, result
II positive events of blood plasma PIVKA- compare when 1 three groups of baby's different days of table
Three groups in different ways after replenishing vitamins K, venous blood blood plasma PIVKA- II is positive when birth the 45th, 90 day, hair
Raw situation is in apparent difference, after 45d experimental group I, experimental group II, control group positive rate be reduced to 2.5% respectively, 0%,
32.5%；Three groups of positive rates are respectively 2.5%, 0%, 15% after 90d, experimental group I, II and control group difference have statistics
Meaning, and positive rate of the test group II in 45d has fallen to 0.In addition, during the experiment, control group has an example injection dimension
After raw element K injections, there is allergic reaction, be discontinued immediately.By experimental result it is found that the drops and dimension of the embodiment of the present invention 5
Raw element K injections and tablet can be such that II positive rates of Neonates PIVKA- decline, but the effect of the present invention is more preferable, and make
Used time occurs without allergic phenomena, safely and effectively.
Embodiment 7
Stability test
1, test method
Drops sample is placed under 4 DEG C of environment and is placed, the solution conditions after observing 0,1,2,3,6,12,18,24 month.
2, test specimen
Sample 1：Commercially available domestic vitamin K drops
Sample 2：Commercially available Germany's production vitamin K drops
Sample 3：2 drops of the embodiment of the present invention
3, test result
The observation result of 1 three kinds of samples of table
As seen from the results in Table 1, under low temperature, in three samples, the stability of sample 1 is worst, and stability of the invention is best,
Place 24 months still clears.
Claims (6)
1. a kind of vitamin K drops, which is characterized in that it is prepared by the raw material of following parts by weight：
0.010-0.013 parts of vitamin K1, farnoquinone 5-6.5,0.2-0.5 parts of vitamin E, casein phosphopeptide 1-3
Part, 64-80 parts of medium chain triglyceride, 25-38 parts of conjugated linoleic acid, 1-3 parts of alginate, tragacanth 3-7, emulsifier 0.5-
2 parts.
2. vitamin K drops as described in claim 1, which is characterized in that it is prepared by the raw material of following parts by weight
's：
0.011-0.012 parts of vitamin K1, farnoquinone 5.5-6,0.3-0.4 parts of vitamin E, casein phosphopeptide 1-2
Part, 70-75 parts of medium chain triglyceride, 30-35 parts of conjugated linoleic acid, 1-2 parts of alginate, 4-6 parts of tragacanth, emulsifier 1-
1.5 part.
3. vitamin K drops as claimed in claim 1 or 2, which is characterized in that the alginate be sodium alginate surround,
And/or potassium alginate.
4. vitamin K drops as claimed in claim 1 or 2, which is characterized in that the emulsifier be polyglyceryl fatty acid ester,
One or more kinds of mixtures in Tween-80, citric acid fatty glyceride.
5. vitamin K drops as claimed in claim 1 or 2, which is characterized in that preparation method includes the following steps：
（1）Vitamin K1, farnoquinone are added in medium chain triglyceride, it is yellow that west is added under conditions of temperature is 38-42 DEG C
Stilbene glue stirs evenly, and is cooled to room temperature, obtains mixed liquor A；
（2）Conjugated linoleic acid and alginate are added in mixed liquor A at room temperature, stirred evenly；
（3）Vitamin E, casein phosphopeptide and emulsifier are continuously added, is stirred evenly, mixed oil liquid is obtained.
6. vitamin K drops as claimed in claim 5, which is characterized in that preparation method is further comprising the steps of：
It will be prepared into capsule-type drops in the mixed oil liquid injection capsule skin of gained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810243587.7A CN108272751A (en) | 2018-03-23 | 2018-03-23 | A kind of vitamin K drops and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810243587.7A CN108272751A (en) | 2018-03-23 | 2018-03-23 | A kind of vitamin K drops and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108272751A true CN108272751A (en) | 2018-07-13 |
Family
ID=62810285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810243587.7A Pending CN108272751A (en) | 2018-03-23 | 2018-03-23 | A kind of vitamin K drops and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108272751A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002104958A (en) * | 2000-09-29 | 2002-04-10 | Sumitomo Chem Co Ltd | Lipophilic vitamin preparation |
| CN1593393A (en) * | 2004-07-09 | 2005-03-16 | 沈阳药科大学 | Prescription of liquid status of Vitamin K1 and its preparation |
| CN102688191A (en) * | 2012-06-20 | 2012-09-26 | 广州安健实业发展有限公司 | Medicine composition containing vitamin K1 and oil |
| CN104825471A (en) * | 2015-04-16 | 2015-08-12 | 王冬 | Vitamin K2 soft capsule and manufacturing process thereof |
-
2018
- 2018-03-23 CN CN201810243587.7A patent/CN108272751A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002104958A (en) * | 2000-09-29 | 2002-04-10 | Sumitomo Chem Co Ltd | Lipophilic vitamin preparation |
| CN1593393A (en) * | 2004-07-09 | 2005-03-16 | 沈阳药科大学 | Prescription of liquid status of Vitamin K1 and its preparation |
| CN102688191A (en) * | 2012-06-20 | 2012-09-26 | 广州安健实业发展有限公司 | Medicine composition containing vitamin K1 and oil |
| CN104825471A (en) * | 2015-04-16 | 2015-08-12 | 王冬 | Vitamin K2 soft capsule and manufacturing process thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张会丰，等: "维生素K滴剂口服改善新生儿维生素K缺乏状况的临床实验研究", 《中国儿童保健杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lauritzen et al. | Maternal fish oil supplementation in lactation: effect on visual acuity and n− 3 fatty acid content of infant erythrocytes | |
| CN105104584B (en) | The preparation method of peony seed oil powdered oil containing active peptide | |
| JP4758898B2 (en) | Solubilized CoQ-10 | |
| JP2023100870A (en) | Method for improving mitophagy in subject | |
| KR20070040379A (en) | Carrier for enteral administration | |
| CN103330734B (en) | Medium/long-chain fat emulsion injection pharmaceutical composition and preparation method thereof | |
| JPH06199663A (en) | Method for therapy of schizophrenia | |
| TW201306752A (en) | Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child | |
| JP5443979B2 (en) | Novel leukotriene receptor antagonist | |
| CN107308111A (en) | One kind contains in olive oil/long chain fat emulsion injection and preparation method thereof | |
| Rosenlund et al. | Dietary essential fatty acids in cystic fibrosis | |
| CN103830204A (en) | Soft capsule containing silybum marianum extract and preparation method of soft capsule | |
| CN108272752A (en) | A kind of farnoquinone drops and preparation method thereof | |
| Davidson et al. | Refractory megaloblastic anemia | |
| CN105963254A (en) | Coenzyme Q10 pharmaceutical composition and preparation process thereof | |
| CN108272751A (en) | A kind of vitamin K drops and preparation method thereof | |
| Schaeffer et al. | Cataract development in animals with delayed supplementation of tryptophane | |
| CN108309951A (en) | A kind of vitamin K1 drops and preparation method thereof | |
| JP2022517518A (en) | Pregnant Beta-Cryptoxanthin Benefits Children | |
| US11147841B2 (en) | Enhanced omega-3 formulations | |
| Rodriguez-Palmero et al. | Administration of low doses of fish oil derived N-3 fatty acids to elderly subjects | |
| CN105663282A (en) | Peony seed oil lipid emulsion and preparation method thereof | |
| CN101244070A (en) | Polyene phosphatidylcholine high-capacity injection | |
| CN104523590B (en) | A kind of Clevidipine butyrate fat emulsion injection | |
| CN114191427B (en) | Medicine for inhibiting platelet activation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180713 |